All Stories

  1. Levodopa-induced lateral jaw deviation dystonia
  2. Gastrointestinal dysfunction in Parkinson's disease
  3. Differentiating atypical parkinsonian syndromes—a way forward?
  4. The Phenotypic Spectrum of Parkinson Disease
  5. Treatment of myoclonus-dystonia syndrome with tetrabenazine
  6. The relationship between obsessive-compulsive symptoms andPARKINgenotype: The CORE-PD study
  7. Gastrointestinal involvement in Parkinson's disease: the horse or the cart
  8. A rare sequence variant in intron 1 of THAP 1 is associated with primary dystonia
  9. Other Neurologic Disorders Associated with Gastrointestinal Disease
  10. Neurologic manifestations of malabsorption syndromes
  11. Beyond here be dragons: SIBO in Parkinson's disease
  12. Catechol-O-methyltransferase inhibitors
  13. Catechol-O-methyltransferase inhibitors
  14. Parkinson’s Disease and Nonmotor Dysfunction
  15. Intestinal Dysfunction in Parkinson’s Disease
  16. Parkinson's Disease, Second Edition
  17. Gastrointestinal Dysfunction in Parkinson’s Disease
  18. Autonomic dysfunction in Parkinson's disease
  19. Annual report 2011
  20. Sentence Intelligibility Before and After Voice Treatment in Speakers With Idiopathic Parkinson’s Disease
  21. Neurogenic Dysphagia
  22. 2.130 CHANGE IN GLUTATHIONE-S-TRANSFERASE-PI EXPRESSION IN BLOOD OF PARKINSON'S DISEASE PATIENTS FOLLOWING EXPOSURE TO OXIDATIVE STRESS: POTENTIAL USE AS A BIOMARKER
  23. Alterations in glutathione S-transferase pi expression following exposure to MPP+-induced oxidative stress in the blood of Parkinson’s disease patients
  24. Gastrointestinal and Swallowing Disturbances in Parkinson's Disease
  25. The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia
  26. Wilson's disease
  27. Gastrointestinal dysfunction in Parkinson’s disease
  28. Frequency of Known Mutations in Early-Onset Parkinson Disease
  29. Predictors of Parkin Mutations in Early-Onset Parkinson Disease
  30. Calcium channel blockers and Parkinson disease
  31. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease
  32. Neurologic Presentations of Gastrointestinal Disease
  33. Annual Report
  34. Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease
  35. Effects of Moderate-Volume, High-Load Lower-Body Resistance Training on Strength and Function in Persons with Parkinson's Disease: A Pilot Study
  36. Impaired leg extensor strength in individuals with Parkinson disease and relatedness to functional mobility
  37. Motor Phenotype of LRRK2 G2019S Carriers in Early-Onset Parkinson Disease
  38. O.056 Gastrointestinal dysfunction in Parkinson's disease
  39. P1.162 Relationship of neuromuscular strength to balance, functional mobility and quality of life in persons with Parkinson's disease
  40. Nonmotor symptoms in Parkinson disease: the PRIAMO study
  41. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease
  42. Alpha-synuclein and familial Parkinson's disease
  43. High-throughput mutational analysis of TOR1A in primary dystonia
  44. Annual report
  45. Consult for a neurohepatologist
  46. Editorial
  47. Effect of Resistance Training on Blood Oxidative Stress in Parkinson Disease
  48. Effect of Resistance Exercise on Blood Oxidative Stress and Antioxidant Status in Parkinson's Disease
  49. Correspondence
  50. Neurogenic Dysphagia
  51. Transdermal drug delivery in Parkinson’s disease
  52. Wilson's Disease
  53. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease
  54. BLADDER AND SEXUAL FUNCTION AND DYSFUNCTION
  55. NEUROLOGY OF GASTROENTEROLOGY AND HEPATOLOGY
  56. Non-motor Parkinsonism
  57. A promising new technology for Parkinson's disease
  58. NEUROLOGICAL DYSFUNCTION IN GASTROINTESTINAL DISEASES
  59. Parkinson’s Disease and Nonmotor Dysfunction
  60. The Phenotypic Spectrum of Parkinson Disease
  61. Advances in Neurology, volume 96: Behavioral neurology of movement disorders, 2nd edition
  62. A multicenter, open-label, sequential study comparingpreferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease
  63. Parkinson's Disease
  64. Gastrointestinal Dysfunction in Parkinson’s Disease
  65. Neurotransplantation in Parkinson’s Disease
  66. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
  67. The PARK8 Locus in Autosomal Dominant Parkinsonism: Confirmation of Linkage and Further Delineation of the Disease-Containing Interval
  68. Longitudinal outcome of Parkinson's disease patients with psychosis
  69. Catechol-o-methyltransferase In Parkinson’s Disease
  70. Development and testing of the Parkinson's disease quality of life scale
  71. Gastrointestinal dysfunction in Parkinson's disease
  72. Anticardiolipin antibody in vascular parkinsonism
  73. Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey
  74. Potential of Transdermal Drug Delivery in Parkinson??s Disease
  75. Brain meets gut: gastroesophageal reflux
  76. Parkinson's disease and movement disorders
  77. Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17): PPND family. A longitudinal videotape demonstration
  78. Book review
  79. Reduced expression of the G209A ?-synuclein allele in familial parkinsonism
  80. Metallothionein in oxidative stress of Parkinson’s disease
  81. Gastrointestinal Motility Problems in Patients with Parkinson???s Disease
  82. Maintenance Electroconvulsive Therapy for Intractable Parkinson's Disease
  83. Neuroleptic Sensitivity to Clozapine in Dementia With Lewy Bodies
  84. Severe bilateral tremor in a liver transplant recipient taking cyclosporine
  85. Maintenance Electroconvulsive Therapy for Intractable Parkinsonʼs Disease
  86. Constipation in parkinson's disease: Objective assessment and response to psyllium
  87. Familial parkinsonism, dementia, and lewy body disease: Study of family G
  88. Editors note:The above letter was referred to the authors of the original paper, and their reply follows
  89. Neurologic Dysfunction in Gastrointestinal Disease
  90. Charles Bonnet Syndrome
  91. Simultaneously evoked primary and cognitive visual evoked potentials distinguish younger and older patients with Parkinson's disease
  92. Antiparkinsonian Agents Drug Interactions of Clinical Significance
  93. Amantadine-induced ?vocal? myoclonus
  94. Cricopharyngeal dysfunction in Parkinson's disease: Role in dysphagia and response to myotomy
  95. Letters to the editor
  96. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease
  97. Anorectal function in fluctuating (on-off) Parkinson's disease: Evaluation by combined anorectal manometry and electromyography
  98. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation
  99. Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture
  100. Gastrointestinal Dysfunction in Parkinson???s Disease
  101. Anorectal manometry in the assessment of anorectal function in Parkinson's disease: A comparison with chronic idiopathic constipation
  102. Distribution of cholinergic and dopaminergic receptors in rainbow trout pineal gland
  103. Defecatory function in Parkinson's disease: Response to apomorphine
  104. The gut in PD
  105. Gastrointestinal dysfunction in Parkinson's disease: Frequency and pathophysiology
  106. CQA 206–291 in Parkinsonʼs Disease
  107. Gastrointestinal symptoms in Parkinson's disease
  108. Bromocriptine-induced hypothermia
  109. Clozapine for psychosis in Parkinson's disease
  110. Dentatorubro-pallidoluysian atrophy of the myoclonus epilepsy type with posterior column degeneration
  111. PONTINE AND EXTRAPONTINE MYELINOLYSIS FOLLOWING LIVER TRANSPLANTATION
  112. ?On-Off?-induced lethal hyperthermia
  113. CQP 201-403 in Parkinson's disease: An open-label pilot study
  114. Cryptococcal meningoencephalitis with parkinsonian features
  115. Low-Dose Bromocriptine Therapy in Parkinson's Disease
  116. The Pharmacology of Mesulergine
  117. Dopamine Receptors
  118. Neurologic Drug Toxicity in the Emergency Room
  119. Treatment of Parkinsonism
  120. Intestinal Dysfunction
  121. Pain Syndromes and Disorders of Sensation